Dr. Thompson is involved in clinical and translational research in urologic oncology and has >200 peer-reviewed original articles. Notable contributions to the literature include discovery that PD-1 and PD-L1 are aberrantly expressed in the microenvironment of renal cell carcinoma tumors, and thus represent attractive therapeutic targets. Dr. Thompson is the recipient of the Donald C. Balfour Award for meritorious research from the Mayo Clinic and the Michael E. Burt Award for Clinical Excellence from Memorial Sloan-Kettering Cancer Center.